CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Real-time Estimate Cboe BZX  -  05/16 03:22:00 pm EDT
25.24 USD   +5.61%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 2 1084 7733 544--
Enterprise Value (EV)1 1 7244 2083 2973 3573 520
P/E ratio -8,25x-19,6x-12,7x-10,9x-9,48x
Yield -----
Capitalization / Revenue -----
EV / Revenue -----
EV / EBITDA -11,6x-19,4x-12,6x-11,2x-10,2x
Price to Book -8,28x199x-24,6x398x
Nbr of stocks (in thousands) 127 124147 236148 289--
Reference price (USD) 16,632,423,923,923,9
Announcement Date 03/24/202103/01/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024
Net sales1 -----
EBITDA1 -149-217-261-299-346
Operating profit (EBIT)1 -149-220-281-329-383
Operating Margin -----
Pre-Tax Profit (EBT)1 -152-225-275-328-383
Net income1 -152-225-275-328-383
Net margin -----
EPS2 -2,01-1,65-1,89-2,20-2,52
Dividend per Share -----
Announcement Date 03/24/202103/01/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 ------
EBITDA ------
Operating profit (EBIT)1 -54,5-64,5-72,5-68,6-69,8-72,9
Operating Margin ------
Pre-Tax Profit (EBT)1 -62,1-59,1-68,3-73,6-76,2-81,2
Net income1 -62,1-59,1-68,3-71,1-70,5-73,9
Net margin ------
EPS2 -0,43-0,40-0,46-0,47-0,48-0,51
Dividend per Share ------
Announcement Date 11/10/202103/01/202205/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt1 -----
Net Cash position1 38456624718724,0
Leverage (Debt / EBITDA) 2,58x2,60x0,95x0,63x0,07x
Free Cash Flow1 -137-189-264-334-397
ROE (Net Profit / Equities) --46,8%-57,2%-69,3%-75,2%
Shareholders' equity1 -482482473509
ROA (Net Profit / Asset) --39,7%-48,7%-60,4%-66,0%
Assets1 -567566542580
Book Value Per Share2 -3,920,12-0,970,06
Cash Flow per Share -----
Capex1 18,910,511,79,939,98
Capex / Sales -----
Announcement Date 03/24/202103/01/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 3 544 117 042
Number of employees 228
Free-Float 81,4%
Free-Float capitalization (USD) 2 885 979 994
Avg. Exchange 20 sessions (USD) 11 917 222
Average Daily Capital Traded 0,34%
EPS & Dividend